Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Äîêàçàòåëüíàÿ ìåäèöèíà

Äîêàçàòåëüíàÿ ìåäèöèíà Ðàçäåë ïðåäíàçíà÷åí äëÿ ïðîôåññèîíàëüíîãî îáùåíèÿ âðà÷åé è ñòóäåíòîâ-ìåäèêîâ ïî âîïðîñàì ìåòîäîëîãèè ÅÂÌ. Êîíñóëüòèðîâàíèå ïàöèåíòîâ â ýòîì ðàçäåëå íå ïðîâîäèòñÿ.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 08.11.2009, 04:14
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,879
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìåòààíàëèç èññëåäîâàíèé ïî ðàçëè÷íûì âèäàì ëå÷åíèÿ âàðèêîçíîé áîëåçíè

Ñðàâíèòåëüíî íåäàâíî áûë îïóáëèêîâàí ìåòààíàëèç èññëåäîâàíèé ïî 4 ðàçëè÷íûì âèäàì ëå÷åíèÿ âàðèêîçíîé áîëåçíè (ÝÕÎ-ñêëåðîîáëèòåðàöèÿ — UGFS, ôëåáýêòîìèÿ — surgery, ðàäèî÷àñòîòíàÿ àáëÿöèÿ - RFA, VNUS, ýíäîâàçàëüíàÿ ëàçåðíàÿ àáëÿöèÿ - EVLA):

J Vasc Surg. 2009 Jan;49(1):230-9. Epub 2008 Aug 9.
Endovenous therapies of lower extremity varicosities: a meta-analysis.
van den Bos R, Arends L, Kockaert M, Neumann M, Nijsten T.

Àáñòðàêò:
Öèòàòà:
BACKGROUND: Minimally invasive techniques such as endovenous laser therapy, radiofrequency ablation, and ultrasound-guided foam sclerotherapy are widely used in the treatment of lower extremity varicosities. These therapies have not yet been compared with surgical ligation and stripping in large randomized clinical trials. METHODS: A systematic review of Medline, Cochrane Library, and Cinahl was performed to identify studies on the effectiveness of the four therapies up to February 2007. All clinical studies (open, noncomparative, and randomized clinical trials) that used ultrasound examination as an outcome measure were included. Because observational and randomized clinical trial data were included, both the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) and Quality Of Reporting Of Meta-analyses (QUORUM) guidelines were consulted. A random effects meta-analysis was performed, and subgroup analysis and meta-regression were done to explore sources of between-study variation. RESULTS: Of the 119 retrieved studies, 64 (53.8%) were eligible and assessed 12,320 limbs. Average follow-up was 32.2 months. After 3 years, the estimated pooled success rates (with 95% confidence intervals [CI]) for stripping, foam sclerotherapy, radiofrequency ablation, and laser therapy were about 78% (70%-84%), 77% (69%-84%), 84% (75%-90%), and 94% (87%-98%), respectively. After adjusting for follow-up, foam therapy and radiofrequency ablation were as effective as surgical stripping (adjusted odds ratio [AOR], 0.12 [95% CI, -0.61 to 0.85] and 0.43 [95% CI, -0.19 to 1.04], respectively). Endovenous laser therapy was significantly more effective compared with stripping (AOR, 1.13; 95% CI, 0.40-1.87), foam therapy (AOR, 1.02; 95% CI, 0.28-1.75), and radiofrequency ablation (AOR, 0.71; 95% CI, 0.15-1.27). CONCLUSION: In the absence of large, comparative randomized clinical trials, the minimally invasive techniques appear to be at least as effective as surgery in the treatment of lower extremity varicose veins.
Ôðàçà, êîòîðóþ ÿ âûäåëèë, óæå èñïîëüçóåòñÿ â ðàçëè÷íûõ âûñòóïëåíèÿõ íà ôëåáîëîãè÷åñêèõ êîíôåðåíöèÿõ êàê îáîñíîâàíèå "òåìïåðàòóðíûõ" ìåòîäîâ ëå÷åíèÿ âàðèêîçíîé áîëåçíè (ðàäèî÷àñòîòíàÿ àáëÿöèÿ è ýíäîâàçàëüíàÿ ëàçåðíàÿ êîàãóëÿöèÿ) êàê áîëåå ýôôåêòèâíûõ, íåæåëè êëàññè÷åñêèé õèðóðãè÷åñêèé ñïîñîá.
Ýòîò âûâîä íàñòîëüêî íå ñîãëàñóåòñÿ ñ ìîåé ëè÷íîé ïðàêòèêîé è ïðàêòèêîé çíàêîìûõ ìíå ôëåáîëîãîâ, ÷òî ïîÿâèëàñü íàñóùíàÿ íåîáõîäèìîñòü îöåíèòü ñîáñòâåííî ïðîâåäåííûé ìåòààíàëèç è ïîíÿòü, ìîæíî ëè âåðèòü ñäåëàííûì â íåì âûâîäàì.
Òàê êàê ÿ ñòàëêèâàþñü ñ ïîäîáíîé íåîáõîäèìîñòüþ âïåðâûå, òî îáðàùàþñü çà ïîìîùüþ è ïðîøó íå ñóäèòü ñòðîãî.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 08.11.2009, 04:16
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,879
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîëíûé òåêñò ìåòààíàëèçà äîñòóïåí â çàêðûòîé ÷àñòè ôîðóìà è ìîæåò áûòü âûñëàí æåëàþùèì ïî ëè÷íîìó çàïðîñó.

Íà ÷òî ÿ îáðàòèë âíèìàíèå ïðè çíàêîìñòâå ñ ïîëíûì òåêñòîì ýòîé ðàáîòû.
Öåëü ñôîðìóëèðîâàíà ñëåäóþùèì îáðàçîì:
Öèòàòà:
The objective of this analysis is to systematically review and summarize the available studies on the surgical and new therapies and compare the effectiveness of these different options in order to assist physicians and patients in selecting the most appropriate intervention for lower extremity varicose veins in the current absence of well-designed RCTs.
Òî åñòü öåëü — ñðàâíåíèå ðåçóëüòàòîâ 4 ðàçëè÷íûõ ìåòîäîâ ëå÷åíèÿ âàðèêîçíîé áîëåçíè ó ëþáûõ ïàöèåíòîâ ñ âàðèêîçíîé áîëåçíüþ.
Êîíå÷íîé òî÷êîé âûáðàíà îöåíêà ñîñòîÿíèÿ «ïðîëå÷åííîé» ìàãèñòðàëüíîé ïîäêîæíîé âåíû (áîëüøàÿ èëè ìàëàÿ ïîäêîæíûå âåíû) ïðè êîíòðîëüíîì óëüòðàçâóêîâîì ñêàíèðîâàíèè. Êîíå÷íàÿ òî÷êà âûãëÿäèò ðàçóìíî, òàê êàê îòñóòñòâèå èëè îáëèòåðàöèÿ ýòîé âåíû, ïî ñîâðåìåííûì ïðåäñòàâëåíèÿì, óñòðàíÿåò îñíîâó âàðèêîçíîé áîëåçíè è âåíîçíîé íåäîñòàòî÷íîñòè, ýòó öåëü è ïðåñëåäóþò âñå 4 ìåòîäèêè.

Âìåñòå ñ òåì:
1.Îòáîð èññëåäîâàíèé äëÿ àíàëèçà.
 îáçîð âêëþ÷åíû êðàéíå ðàçíîðîäíûå èññëåäîâàíèÿ, êàê êîíòðîëèðóåìûå, òàê è ïðîñïåêòèâíûå è ðåòðîñïåêòèâíûå ñåðèè ñëó÷àåâ. 89% âêëþ÷åííûõ èññëåäîâàíèé áûëè îïèñàíèåì ñåðèè ñëó÷àåâ.
 ãðóïïå õèðóðãè÷åñêèõ ìåòîäîâ îêàçàëîñü 5 ÐÊÈ, êîòîðûå îõâàòèëè 115 «íîã» (â ñðåäíåì â èññëåäîâàíèå âõîäèëî âñåãî ëèøü ïî 23 ïàöèåíòà) ñî ñëåäóþùèìè ñðîêàìè íàáëþäåíèÿ (â ìåñÿöàõ): 3; 1; 1.5; 24; 36. ×òî ìîæíî ïîñëå îïåðàöèè îöåíèâàòü ÷åðåç îäèí ìåñÿö — äàæå òðóäíî ïðåäñòàâèòü.  ãðàôå «Definition of failure» íåðåäêî ñòîèò «Recurrent/newvarices», êàê òî ýòî íå âÿæåòñÿ ñ âûáðàííîé êîíå÷íîé òî÷êîé. Íóæíî ñìîòðåòü îðèãèíàëû èññëåäîâàíèé è ïðîâåðÿòü, â êàêîì ñîñòîÿíèè áûëà «ïðîëå÷åííàÿ» ïîäêîæíàÿ âåíà íà ÓÇÈ? Îáùèé ðåçóëüòàò óñïåõà õèðóðãè÷åñêîãî ëå÷åíèÿ ìåíåå 80% â ñòîëü ðàííèå ñðîêè íàáëþäåíèÿ íàâîäèò íà ðàçìûøëåíèÿ — íå ïîó÷àåòñÿ íîðìàëüíî óäàëèòü êàæäóþ ïÿòóþ âåíó? Ïðèìåðíî òàêèå æå âîïðîñû âîçíèêàþò è ïî äðóãèì ãðóïïàì.
Êàê îöåíèâàëîñü êà÷åñòâî òåõ íåìíîãèõ ÐÊÈ, êîòîðûå âêëþ÷åíû â îáçîð, ÿ íå ïîíÿë.

2.Ïàöèåíòû.
Íà ïåðâûé âçãëÿä, ðàçíîðîäíîñòü ïàöèåíòîâ â ðàçíûõ èññëåäîâàíèÿõ — ïóòü ê ñèñòåìàòè÷åñêîé îøèáêå. Äåëî â òîì, ÷òî è ÝÕÎ-ñêëåðîîáëèòåðàöèÿ, è «òåìïåðàòóðíûå ìåòîäû» îðèåíòèðîâàíû íà âàðèêîç ñ óìåðåííûì äèàìåòðîì ìàãèñòðàëüíîé âåíû, âî ìíîãèõ ãàéäàõ ïðîïèñûâàþòñÿ ðåêîìåíäàöèè íå ïðèìåíÿòü ýòè ìåòîäèêè ïðè äèàìåòðå îñíîâíîãî ñòâîëà áîëåå 1.0 — 1.2 ñì. Ôëåáýêòîìèÿ, íàïðîòèâ, íå çíàåò òàêîãî îãðàíè÷åíèÿ. È ñîâåðøåííî ëîãè÷íî ïðåäïîëàãàòü ðàçíûå ðåçóëüòàòû ó ðàçíûõ áîëüíûõ óæå èç-çà ðàçíîñòè èñõîäíûõ äèàìåòðîâ âåí è òÿæåñòè âàðèêîçà. Ñ äðóãîé ñòîðîíû, åñëè êîí÷åíàÿ òî÷êà — îòñóòñòâèå èëè îáëèòåðàöèÿ âåíû, òî ïðè óäàëåíèè õèðóðãè÷åñêèì ïóòåì íàì ñîâåðøåííî íåò ðàçíèöû, êàêîâ áûë åå èñõîäíûé äèàìåòð. Âîò äëÿ âñåõ ñêëåèâàþùèõ ìåòîäîâ ýòî ìîæåò áûòü çíà÷èìî, íî àâòîðû âåäü ïîêàçûâàþò äëÿ õèðóðãèè ìåíüøóþ ýôôåêòèâíîñòü.
Âîïðîñ: âîçìîæíî ëè, ÷òî ïðè âûáðàííîé êîíå÷íîé òî÷êå ðàçíîðîäíîñòü ãðóïï áîëüíûõ, ê êîòîðûì ïðèìåíÿëîñü âìåøàòåëüñòâî, íå ïðèâåëà ê îøèáêå â âûâîäàõ?

3.Îöåíêà ðåçóëüòàòà.
Àâòîðû îïèñûâàþò îòáîð òåðìèíîâ, ïðèìåíåííûõ â îïèñàíèè ðåçóëüòàòîâ èññëåäîâàíèé, êîòîðûé, íà èõ âçãëÿä, ñíèæàåò âåðîÿòíîñòü îøèáêè íà ýòîì ýòàïå.
Òî åñòü, îíè èñêëþ÷èëè èññëåäîâàíèÿ, ãäå çâó÷àò ôðàçû òèïà «÷àñòè÷íàÿ ðåêàíàëèçàöèÿ», «óëó÷øåíèå» è ò.*ï., à îòîáðàëè òå, ãäå ê «ïðîëå÷åííûì» âåíàì ïðèìåíåíû òåðìèíû: «îòñóòñòâèå», «îáëèòåðàöèÿ» è ò.*ï. Òèïà — èëè åñòü, èëè íåò. Âðîäå áû íîðìàëüíî, íî ñðàçó âîçíèêàåò âîïðîñ. Ïðåäïîëîæèì, åñòü ÐÊÈ ïî ôëåáýêòîìèè â ñðàâíåíèè ñ ÷åì-òî. Ïîëó÷èëè 80% óñïåõà ïðè îïåðàöèè. À îñòàâøèåñÿ 20% - åñëè íå ïîëíîå îòñóòñòâèå âåíû, òî ýòî åå ïîëíîå ïðèñóòñòâèå? Îïÿòü âîçíèêàåò æåëàíèå ïîñìîòðåòü ïåðâîèñòî÷íèê, èëè ÿ íåïðàâèëüíî ðàññóæäàþ?

4.×òî áûëî áû, åñëè áû àâòîðû îñòàâèëè òîëüêî ÐÊÈ?
×åñòíî ãîâîðÿ, òàê è íå ïîíÿë, ÷òî áûëî áû
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 08.11.2009, 21:42
Àâàòàð äëÿ o_udovichenko
o_udovichenko o_udovichenko âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 25.05.2007
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 1,052
Ïîáëàãîäàðèëè 118 ðàç(à) çà 101 ñîîáùåíèé
o_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåo_udovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Iluhin Ïîñìîòðåòü ñîîáùåíèå
2.Ïàöèåíòû.
Íà ïåðâûé âçãëÿä, ðàçíîðîäíîñòü ïàöèåíòîâ â ðàçíûõ èññëåäîâàíèÿõ — ïóòü ê ñèñòåìàòè÷åñêîé îøèáêå. Äåëî â òîì, ÷òî è ÝÕÎ-ñêëåðîîáëèòåðàöèÿ, è «òåìïåðàòóðíûå ìåòîäû» îðèåíòèðîâàíû íà âàðèêîç ñ óìåðåííûì äèàìåòðîì ìàãèñòðàëüíîé âåíû, âî ìíîãèõ ãàéäàõ ïðîïèñûâàþòñÿ ðåêîìåíäàöèè íå ïðèìåíÿòü ýòè ìåòîäèêè ïðè äèàìåòðå îñíîâíîãî ñòâîëà áîëåå 1.0 — 1.2 ñì. Ôëåáýêòîìèÿ, íàïðîòèâ, íå çíàåò òàêîãî îãðàíè÷åíèÿ. È ñîâåðøåííî ëîãè÷íî ïðåäïîëàãàòü ðàçíûå ðåçóëüòàòû ó ðàçíûõ áîëüíûõ óæå èç-çà ðàçíîñòè èñõîäíûõ äèàìåòðîâ âåí è òÿæåñòè âàðèêîçà. Ñ äðóãîé ñòîðîíû, åñëè êîí÷åíàÿ òî÷êà — îòñóòñòâèå èëè îáëèòåðàöèÿ âåíû, òî ïðè óäàëåíèè õèðóðãè÷åñêèì ïóòåì íàì ñîâåðøåííî íåò ðàçíèöû, êàêîâ áûë åå èñõîäíûé äèàìåòð. Âîò äëÿ âñåõ ñêëåèâàþùèõ ìåòîäîâ ýòî ìîæåò áûòü çíà÷èìî, íî àâòîðû âåäü ïîêàçûâàþò äëÿ õèðóðãèè ìåíüøóþ ýôôåêòèâíîñòü.
Âîïðîñ: âîçìîæíî ëè, ÷òî ïðè âûáðàííîé êîíå÷íîé òî÷êå ðàçíîðîäíîñòü ãðóïï áîëüíûõ, ê êîòîðûì ïðèìåíÿëîñü âìåøàòåëüñòâî, íå ïðèâåëà ê îøèáêå â âûâîäàõ?
Äà, âîò ýòà ìûñëü ñðàçó âîçíèêàåò ïðè ÷òåíèè: äëÿ ìàëîèíâàçèâíûõ ìåòîäèê ëå÷åíèÿ îòáèðàþòñÿ ïàöèåíòû ñ ìåíåå òÿæåëîé âàðèêîçíîé áîëåçíüþ.
Ïîýòîìó ñðàâíèâàòü ýôôåêòèâíîñòü õèðóðãè÷åñêîãî è àëüòåðíàòèâíûõ ìåòîäîâ "ëîá â ëîá" ìîæíî áûëî áû ëèøü ïî ðåçóëüòàòàì ÐÊÈ (è òî, â òàêîå èññëåäîâàíèå äîëæíû âêëþ÷àòüñÿ ïàöèåíòû ñ íåòÿæåëûûì âàðèêîçîì - êîòîðûì ìîæíî ïðèìåíÿòü îáà ìåòîäà ëå÷åíèÿ. Ïîýòîìó ýêñòðàïîëèðîâàòü åãî äàííûå íà îáùóþ ïîïóëÿöèþ áîëüíûõ íàäî ñ îñòîðîæíîñòüþ).
Ñ äðóãîé ñòîðîíû, àâòîðû ìåòà-àíàëèçà âåäü ÷åñòíî ïèøóò, ÷òî öåëü - ïðîâåñòè õîòü êàêîå-òî ñðàâíåíèå â îòñóòñòâèå äîñòàòî÷íîãî êîëè÷åñòâà ÐÊÈ ïî äàííîé ïðîáëåìå. È âûâîäû, íàñêîëüêî ÿ ïîíèìàþ, äåëàþò îñòîðîæíî.

Ìíå êàæåòñÿ, ÷òî ãëàâíûé âûâîä, êîòîðûé íå âûçîâåò îñîáîé êðèòèêè - ÷òî â ïðàâèëüíî îòîáðàííîé ïîäãðóïïå áîëüíûõ ìîæíî ïðîâîäèòü ìàëîèíâàçèâíîå ëå÷åíèå, è åãî ðåçóëüòàòèâíîñòü äîñòàòî÷íî âûñîêà è íå óñòóïàåò ðåçóëüòàòèâíîñòè õèðóðãè÷åñêîãî ëå÷åíèÿ (ïî êðàéíåé ìåðå, ðàññ÷èòàííîé äëÿ îáùåé ìàññû áîëüíûõ, ïîäâåðãàåìûõ "êëàññè÷åñêîé" õèðóðãèè ïðè ÂÐÂ).
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 09.11.2009, 19:58
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,879
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
ãëàâíûé âûâîä, êîòîðûé íå âûçîâåò îñîáîé êðèòèêè - ÷òî â ïðàâèëüíî îòîáðàííîé ïîäãðóïïå áîëüíûõ ìîæíî ïðîâîäèòü ìàëîèíâàçèâíîå ëå÷åíèå, è åãî ðåçóëüòàòèâíîñòü äîñòàòî÷íî âûñîêà è íå óñòóïàåò ðåçóëüòàòèâíîñòè õèðóðãè÷åñêîãî ëå÷åíèÿ (ïî êðàéíåé ìåðå, ðàññ÷èòàííîé äëÿ îáùåé ìàññû áîëüíûõ, ïîäâåðãàåìûõ "êëàññè÷åñêîé" õèðóðãèè ïðè ÂÐÂ)
Ñ òàêîé ôîðìóëèðîâêîé ÿ íå ñïîðþ. Âîïðîñ íåìíîãî â äðóãîì – îájñíîâàíèåì äëÿ ýòîãî, äîñòàòî÷íî êîððåêòíîãî, âûâîäà, ñëóæàò öèôðû, êîòîðûå èíîãäà ïðåïîäíîñÿòñÿ ñîâñåì â äðóãîì ñâåòå. È ÿ õî÷ó ïîíÿòü, êîððåêòíû ëè ýòè öèôðû (âûäåëåíû â àáñòðàêòå ñòàòüè â ïåðâîì ïîñòå). Àâòîðû êîíêðåòíî çàÿâëÿþò: In the absence of comparative RCTs, it appears that EVLA is more effective than surgery, UGFS, and RFA.

Äàëüíåéøèå çàìå÷àíèÿ è ðàññóæäåíèÿ ïî ìåòààíàëèçó.
• Êàê ÿ ïîíÿë, ìåòààíàëèç ìîæåò ïðîâîäèòüñÿ ïî èññëåäîâàíèÿì ðàçíîãî äèçàéíà, íî òîãäà îíè äîëæíû èìåòü ðàçíûé «âåñ» ïðè ðàñ÷åòàõ. Ãäå ýòî äîëæíî áûòü óêàçàíî?
• Âåñüìà âåðîÿòíî, ÷òî íåêîòîðûå èññëåäîâàíèÿ ñ ïðèìåíåíèåì ðàäèî÷àñòîòíîé èëè ëàçåðíîé îáëèòåðàöèè ôèíàíñèðîâàíû ïðîèçâîäèòåëåì àïïàðàòóðû. Ïðî êîíôëèêò èíòåðåñîâ âèæó òîëüêî: Case series and the arms of interest of RCTs were entered separately in the analysis.
• ÐÊÈ – ÐÊÈ ðîçíü. Áðîñèëèñü â ãëàçà î÷åíü ìàëåíüêàÿ ìîùíîñòü è êîðîòêèé ñðîê íàáëþäåíèÿ â íåêîòîðûõ óêàçàííûõ â îáçîðå ÐÊÈ. Ïîñåìó ÿ íàøåë àáñòðàêòû íà âñå ÐÊÈ èç ìåòààíàëèçà è ïîçíàêîìèëñÿ ñ íèìè ïîáëèæå:

1.
Öèòàòà:
Eur J Vasc Endovasc Surg. 2006 Jan;31(1):93-100. Epub 2005 Oct 17. Ultrasound-guided foam sclerotherapy combined with sapheno-femoral ligation compared to surgical treatment of varicose veins: early results of a randomised controlled trial. Bountouroglou DG, Azzam M, Kakkos SK, Pathmarajah M, Young P, Geroulakos G.
Êîíòðîëü ÓÇÈ è êàêàÿ áû òî íè áûëî îöåíêà ñîñòîÿíèÿ «îáðàáîòàííîé » âåíû ïîñëå ëå÷åíèÿ ÍÅ ÏÐÎÂÎÄÈËÈÑÜ! Íå ãîâîðÿ î íåêîòîðûõ äðóãèõ ñóùåñòâåííûõ çàìå÷àíèÿõ. Êîíå÷íûå òî÷êè ýòîãî ÐÊÈ: Primary end points were patient recovery period and quality of life and secondary end points frequency of complications on the two arms of the trial and the cost of the treatment.
2.
Öèòàòà:
Dermatol Surg. 2005 Dec;31(12):1685-94; discussion 1694. Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins. de Medeiros CA, Luccas GC.
Ìàêñèìàëüíûé ñðîê íàáëþäåíèÿ – âñåãî 60 äíåé! Èññëåäîâàíèå èíòåðåñíîå – îäíó íîãó æãëè ëàçåðîì, íà äðóãîé âåíû óäàëÿëè.  àáñòðàêòå íè÷åãî íå ñêàçàíî, íàñêîëüêî áûëà ñîïîñòàâèìà òÿæåñòü âàðèêîçà, ïàðàìåòðû âåí. È äîñòàòî÷íî ëè ñëó÷àéíî ðàñïðåäåëèòü âìåøàòåëüñòâî, ÷òîáû íèâåëèðîâàòü ýòîò ôàêòîð – òóò íóæíî ÿñíî ïîíèìàòü, êàê ðàíäîìèçàöèÿ ïðîâîäèëàñü. À òî âäðóã ëàçåð è îïåðàöèè ðàâíîìåðíî ðàñïðåäåëèëè ïî ïðàâûì è ëåâûì íîãàì, à îêàæåòñÿ ÷òî âàðèêîç íà ïðàâîé îáû÷íî áûë òÿæåëåå, ÷åì íà ëåâîé. Íî ñàìîå ëþáîïûòíîå, ÷òî óêàçûâàåòñÿ îäíà ðåêàíàëèçàöèÿ âåíû ïîñëå ëàçåðà – è íè ñëîâà î íåóäà÷àõ õèðóðãè÷åñêîãî ìåòîäà.
3.
Öèòàòà:
Eur J Vasc Endovasc Surg. 2006 Feb;31(2):212-8. Epub 2005 Aug 31. A prospective randomised controlled trial of VNUS closure versus surgery for the treatment of recurrent long saphenous varicose veins. Hinchliffe RJ, Ubhi J, Beech A, Ellison J, Braithwaite BD.
Ñòðàííî, íî èññëåäîâàíèå êàñàåòñÿ ëå÷åíèÿ ÐÅÖÈÄÈÂÍÎÃÎ âàðèêîçà íà îáåèõ êîíå÷íîñòÿõ. À ýòî îòäåëüíàÿ òåìà, îíî âîîáùå äîëæíî áûòü èñêëá÷åíî èç ìåòààíàëèçà. Ê ñîæàëåíèþ èç àáñòðàêòà íåÿñíî, íà êàêîì ñðîêå ïðîâîäèëîñü êîíòðîëüíîå óëüòðàçóêîâîå èññëåäîâàíèå.
4.
Öèòàòà:
Eur J Vasc Endovasc Surg. 2005 Jan;29(1):67-73. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Lurie F, Creton D, Eklof B, Kabnick LS, Kistner RL, Pichot O, Sessa C, Schuller-Petrovic S.
Ïîõîæå, ïðèëè÷íîå èññëåäîâàíèå. Ñðàâíåíèå ðàäèî÷àñòîòíîé îáëèòðàöèè è õèðóðãèè. Îáùåå êîëè÷åñêòâî ïàöèåíòîâ, ñêîëüêî ïàöèåíòîâ âûáûëî èç èññëåäîâàíèÿ - ïî àáñòðàêòó íåÿñíî, ñðîê íàáëþäåíèÿ – äâà ãîäà. Ñóäÿ ïî ôðàçå èç àáñòðàêòà ìîùíîñòü ìàëåíüêàÿ è àâòîðû îñòîðîæíè÷àþò â îöåíêå ïîëó÷åííûõ äàííûõ.
5.
Öèòàòà:
Ann Vasc Surg. 2005 Sep;19(5):669-72. Radiofrequency endovenous obliteration versus stripping of the long saphenous vein in the management of primary varicose veins: 3-year outcome of a randomized study. Perala J, Rautio T, Biancari F, Ohtonen P, Wiik H, Heikkinen T, Juvonen T.
Ñèìïàòè÷íîå èññëåäîâàíèå èç Ôèíëÿíäèè. Ñðîê íàáëþäåíèÿ -3 ãîäà. Êîíå÷íûå òî÷êè íå ñîîòâåòñòâóþò öåëÿì ìåòààíàëèçà, íî ÓÇÈ êîíòðîëü ïðîâîäèëñÿ è ñîñòîÿíèå ìàãèñòðàëüíîé ïîäêîæíîé âåíû îöåíèâàëîñü. Êàê ÿ ïîíÿë, íåóäà÷à òîëüêî îäíà – îáíàðóæåí äîáàâî÷íûé ñòâîë áîëüøîé ïîäêîæíîé âåíû â õèðóðãè÷åñêîé ãðóïïå. Ïðàâäà, ñðàçó âîçíèêàåò âîïðîñ – ïî÷åìó ýòî ñîñòîÿíèå íå áûëî äèàãíîñòèðîâàíî äî ëå÷åíèÿ, ïàöèåíò âêëþ÷åí â èññëåäîâàíèå, à âåíà â êîíå÷íîì èòîãå íå óäàëåíà? Êñòàòè, âûâîä ïî êîíå÷íîé òî÷êå â âèäå ïîÿâëåíèÿ ðåöèäèâíûõ âåí â áàññåéíå âìåøàòåëüñòâà: According to the present results, radiofrequency endovenous obliteration of the LSV is associated with somewhat poorer short-term results compared with the stripping operation.
6.
Öèòàòà:
Angiology. 2000 Jul;51(7):529-34. Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results. Belcaro G, Nicolaides AN, Ricci A, Dugall M, Errichi BM, Vasdekis S, Christopoulos D.
Ïîòðÿñàþùå!  ãðóïïå õèðóðãè÷åñêèõ îïåðàöèé ÑÒÂÎË ÍÅ ÓÄÀËßËÑß! Äåëàëè ïåðåâÿçêó â îáëàñòè ñàôåíî-ôåìîðàëüíîãî ñîóñòüÿ è óäàëåíèå ïðèòîêîâ. Ñ êàêîé ñòàòè ýòî èññëåäîâàíèå âêëþ÷åíî â ìåòààíàëèç?  òàáëèöå âêëþ÷åííûõ èññëåäîâàíèé îíî èäåò â ãðóïïå èññëåäîâàíèé ïî ÝÕÎñêëåðîòåðàïèè, òî åñòü ó÷èòûâàëè òîëüêî äàííûå ïàöèåíòîâ, ïîëó÷àþùèõ ñêëåðîòåðàïèþ? (Òîãäà ïðè ÷åì òóò ÐÊÈ?) Êàêîâû ýòè äàííûå íå î÷åíü ÿñíî, òàê êàê â àáñòðàêòå íè÷åãî íå ãîâîðèòñÿ îá îöåíêå ñîñòîÿíèÿ ìàãèñòðàëüíîé âåíû.
Òî æå ñàìîå êàñàåòñÿ âòîðîãî èññëåäîâàíèÿ ýòèõ àâòîðîâ:
Öèòàòà:
Angiology. 2003 May-Jun;54(3):307-15. Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). Belcaro G, Cesarone MR, Di Renzo A, Brandolini R, Coen L, Acerbi G, Marelli C, Errichi BM, Malouf M, Myers K, Christopoulos D, Nicolaides A, Geroulakos G, Vasdekis S, Simeone E, Ricci A, Ruffini I, Stuard S, Ippolito E, Bavera P, Georgiev M, Corsi M, Scoccianti M, Cornelli U, Caizzi N, Dugall M, Christopoulos D, Veller M, Venniker R, Cazaubon M, Griffin M.
Õèðóðãè÷åñêèì ëå÷åíèåì çäåñü, ïî÷åìó-òî, íàçûâàþò ëèãèðîâàíèå ñàôåíîôåìîðàëüíîãî ñîóñòüÿ ñ ïîñëåäóþùåé ñêëåðîòåðàïèåé. ×òî åñòü íåêîððåêòíî, òî åñòü îá ÐÊÈ, êîòîðîå ïîäõîäèò äëÿ âêëþ÷åíèÿ â ìåòààíàëèç îïÿòü ðå÷è íåò.  ìåòààíàëèçå:
Öèòàòà:
Inclusion criteria. Our meta-analysis included RCTs, clinical trials, and prospective and retrospective case series on the treatment of human lower extremity varicosities by surgical stripping (SFJ ligation and GSV stripping … Exclusion criteria. Studies that performed SFJ ligation without stripping were excluded because this approach is considered suboptimal.
Ìîæåò áûòü â ïîëíîì òåêñòå åñòü ñòàòèñòèêà ïî ñîñòîÿíèþ ìàãèñòðàëüíûõ âåí ïîñëå ñêëåðî è àâòîðû èñïîëüçîâàëè åå?

Âîò è âñå, áîëüøå ÐÊÈ íåò. Êàê-òî âñå ñòðàííåå è ñòðàííåå.
Ìîãó ëè ÿ ñêàçàòü òàêèì îáðàçîì: â àíàëèç íå âêëþ÷åíû ñðàâíèòåëüíûå èññëåäîâàíèÿ, ïîçâîëÿþùèå ñðàâíèòü ýôôåêòèâíîñòü õèðóðãè÷åñêîé îïåðàöèè è ìàëîèíâàçèâíûõ ìåòîäèê ïî ëþáûì ïðèçíàêàì. Ïðåäñòàâëåííàÿ â âûâîäàõ àâòîðîâ ñòàòèñòèêà íå îòðàæàåò èñòèííîãî ñîîòíîøåíèÿ ýôôåêòèâíîñòè ðàçëè÷íûõ ñïîñîáîâ ëå÷åíèÿ âàðèêîçíîé áîëåçíè. Âûâîä î òîì, ÷òî ëàçåðíàÿ êîàãóëÿöèÿ â îòñóòñòâèè ÐÊÈ ïðåäñòàâëÿåòñÿ áîëåå ýôôåêòèâíîé, ÷åì òðè äðóãèå ñðàâíèâàåìûå ìåòîäèêè ëå÷åíèÿ íåêîððåêòåí.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 11.11.2009, 15:22
LupusDoc LupusDoc âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 04.08.2007
Ãîðîä: RUSSIA
Ñîîáùåíèé: 4,176
Ïîáëàãîäàðèëè 1,091 ðàç(à) çà 998 ñîîáùåíèé
LupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ýíäîâàñêóëÿðíûå ìåòîäû ëå÷åíèÿ âàðèêîçíûõ âåí íèæíèõ êîíå÷íîñòåé: àíàëèç ìåòà-àíàëèçà

«Ýíäîâàñêóëÿðíûå ìåòîäû ëå÷åíèÿ âàðèêîçíûõ âåí íèæíèõ êîíå÷íîñòåé: ìåòà-àíàëèç» - òàê íàçûâàåòñÿ ñòàòüÿ. È òàêîå íàçâàíèå âïîëíå îòðàæàåò ñîäåðæàíèå, íî íè÷åãî íå ãîâîðèò î êà÷åñòâå ðàáîòû.
Ïåðâûé âîïðîñ, êîòîðûé òðåáóåò îòâåòà – ÿâëÿåòñÿ ëè äàííàÿ ðàáîòà ñèñòåìàòè÷åñêèì îáçîðîì? Ñèñòåìàòè÷åñêèå îáçîðû îòëè÷àþòñÿ îò òðàäèöèîííûõ «îïèñàòåëüíûõ» (“narrative”) îáçîðîâ òåì, ÷òî âûïîëíÿåòñÿ ïîèñê âñåõ, à íå òîëüêî ïîëþáèâøèõñÿ àâòîðàì, èñòî÷íèêîâ äîêàçàòåëüñòâ è âñå îíè ðàññìàòðèâàþòñÿ â êîíòåêñòå êëèíè÷åñêîãî âîïðîñà. Ñèñòåìàòè÷åñêèå îáçîðû ìîãóò (íî íå äîëæíû) ñîïðîâîæäàòüñÿ ìåòà-àíàëèçîì ðåçóëüòàòîâ, íî è áåç ìåòà-àíàëèçà ñèñòåìàòè÷åñêèé îáçîð èìååò áîëüøóþ öåííîñòü.

Èññëåäîâàíèå ðàçäåëà «ìåòîäû» ïîçâîëÿåò óòâåðæäàòü, ÷òî äàííàÿ ðàáîòà ÿâëÿåòñÿ ñèñòåìàòè÷åñêèì îáçîðîì, ïîñêîëüêó èìåþòñÿ ÷åòêèå êðèòåðèè ïîèñêà ïóáëèêàöèé, èõ âêëþ÷åíèÿ è èñêëþ÷åíèÿ. Íåëüçÿ íàçâàòü äàííûé ñèñòåìàòè÷åñêèé îáçîð âñåîáúåìëþùèì è ïî îõâàòó áèáëèîãðàôè÷åñêèõ áàç äàííûõ îí óñòóïàåò Êîêðàíîâñêèì îáçîðàì, íî òåì íå ìåíåå ìîæíî ñ÷èòàòü, ÷òî âñå îñíîâíûå ïóáëèêàöèè ïî ïðîáëåìå áûëè îáíàðóæåíû. Àâòîðû îòìå÷àþò, ÷òî 89% âêëþ÷åííûõ â îáçîð èññëåäîâàíèé áûëè îïèñàíèÿìè ñåðèé ñëó÷àåâ, à íà ÐÊÈ ïðèõîäèòñÿ òîëüêî ìàëàÿ äîëÿ. Ïîýòîìó ãîâîðèòü î òîì, ÷òî íà îñíîâàíèè àíàëèçà ñåðèé ñëó÷àåâ ìîæíî ñäåëàòü äîñòîâåðíûå âûâîäû îá ýôôåêòèâíîñòè âìåøàòåëüñòâ íå ïðèõîäèòñÿ. Òåì íå ìåíåå, â îòñóòñòâèå äîêàçàòåëüñòâ áîëåå âûñîêîãî óðîâíÿ âðà÷ äîëæåí îïèðàòüñÿ íà íàèëó÷øèå èç èìåþùèõñÿ ê íàñòîÿùåìó âðåìåíè è èçó÷åíèå ñåðèé ñëó÷àåâ â îòñóòñòâèå ÐÊÈ âàæíî.

Îäíàêî àâòîðû ïðèíÿëè ðåøåíèå âûïîëíèòü íå òîëüêî êà÷åñòâåííûé, íî è êîëè÷åñòâåííûé àíàëèç ðåçóëüòàòîâ. Äëÿ òîãî, ÷òîáû èìåëàñü òåõíè÷åñêàÿ âîçìîæíîñòü âûïîëíèòü òàêîé àíàëèç èì ïðèøëîñü ïðèáåãíóòü ê «ïðîèçâîëüíîìó èñõîäó», ò.å. îí ñàìè îïðåäåëÿëè óñïåøíîñòü èëè íåóñïåøíîñòü ëå÷åíèÿ ïî ÓÇÈ-ïàðàìåòðàì, ïðè÷åì ñîâåðøåííî íåîáÿçàòåëüíî ýòè ÓÇÈ-ïàðàìåòðû ÿâëÿëèñü ïåðâè÷íûìè êîíå÷íûìè òî÷êàìè â ÐÊÈ èëè îñíîâíîé ìåðîé ýôôåêòà â îïèñàíèÿõ ñåðèé ñëó÷àåâ. Ïðîèçâîëüíîñòü òðàêòîâêè àâòîðîâ ïðèâîäèò ê ôîðìèðîâàíèþ ñèñòåìàòè÷åñêîé îøèáêè îòáîðà èññëåäîâàíèé, êîòîðóþ îíè ñàìè óñóãóáëÿþò äàëåå: Studies that reported “clinical improvement,” “patient satisfaction,” “reflux at any site,” “varicose veins present anywhere,” and others were excluded – ïðîèçâîëüíî èñêëþ÷àÿ ðÿä èññëåäîâàíèé.

Ñëåäóþùèì øàãîì ÿâëÿëîñü ñîçäàíèå ìîäåëè äëÿ ïðîâåäåíèÿ ìåòà-àíàëèçà îáñåðâàöèîííûõ èññëåäîâàíèé è àâòîðû ðàñ÷ëåíÿþò äëÿ ýòîãî ÐÊÈ íà îòäåëüíûå ñòðàòû, íèçâîäÿ òåì ñàìûì ÐÊÈ äî óðîâíÿ îïèñàíèé ñåðèé ñëó÷àåâ. Áåç òàêîãî «ìàíåâðà» îáîéòèñü áûëî íåëüçÿ, åñëè àâòîðû õîòåëè òàêè ëþáîé öåíîé âûïîëíèòü êîëè÷åñòâåííûé àíàëèç – èáî íåâîçìîæíî ñðàâíèâàòü ÿáëîêè ñ àïåëüñèíàìè. Ðåçóëüòàòîì íåèìîâåðíîãî ñòàòèñòè÷åñêîãî èçîùðåíèÿ ñòàëà ìîäåëü, ïîíÿòíàÿ òîëüêî àâòîðàì. Õîòÿ ÿ ñîìíåâàþñü, ÷òî îíà ïîíÿòíà âñåì àâòîðàì, à íå òîëüêî ñòàòèñòèêó Ëèäèè Àðåíäñ. Äëÿ ñòàòèñòèêà ñëîæíàÿ ìîäåëü ïðåäñòàâëÿåòñÿ èíòåðåñíîé çàäà÷åé, à òîò ôàêò, ÷òî îíà ëèøåíà êëèíè÷åñêîãî íàïîëíåíèÿ åãî ñèëüíî íå áåñïîêîèò. Ðåçóëüòàòîì ñòàë «ñôåðè÷åñêèé êîíü â âàêóóìå» - íåêàÿ ìíîãîìåðíàÿ ìîäåëü ñ îäíîé äëÿ âñåõ èññëåäîâàíèé îáùåé ñëó÷àéíîé âåëè÷èíîé – íî, ñêàæèòå íà ìèëîñòü, ÷òî æå òàêîãî ãåíåðàëüíî îáùåãî âî âñåõ âêëþ÷åííûõ èññëåäîâàíèÿõ - êðîìå âåí íèæíèõ êîíå÷íîñòåé – ÷òî ìîæåò îáúÿñíèòü íàëè÷èå ýòîé îáùåé ïåðåìåííîé?
È äàæå ýòî ïîëáåäû, íî ñëåäóþùèì øàãîì ñòàëî ïðîâåäåíèå ìåòà-ðåãðåññèè – ýòîò ñòàòèñòè÷åñêèé èçûñê â íàñòîÿùåå âðåìÿ àêòèâíî îáñóæäàåòñÿ è ïîêà îáùèì çíàìåíàòåëåì ÿâëÿåòñÿ òî, ÷òî ìåòà-ðåãðåññèþ íå ñëåäóåò èñïîëüçîâàòü äëÿ îêîí÷àòåëüíîãî çàêëþ÷åíèÿ îá ýôôåêòèâíîñòè âìåøàòåëüñòâ, íî îíà ìîæåò áûòü ïîëåçíûì ãèïîòåçà-ãåíåðèðóþùåì ìåòîäîì. Êàê ýòî íè ïå÷àëüíî, íî èìåííî ìåòà-ðåãðåññèÿ â äàííîì àíàëèçå ñòàëà îïðåäåëÿþùèì ìåòîäîì àíàëèçà ýôôåêòèâíîñòè…

Êàê è âî âñåõ äðóãèõ îáëàñòÿõ, îò êà÷åñòâà èñõîäíûõ ïðîäóêòîâ (äàííûõ) çàâèñèò êà÷åñòâî ãîòîâîãî áëþäà (àíàëèçà). Ìåòà-àíàëèç íå ìîæåò äàòü ëó÷øèå äàííûå ÷åì ïîñëóæèâøèå îñíîâîé äëÿ íåãî èñõîäíûå ðåçóëüòàòû èññëåäîâàíèé è èç «ïëîõèõ» èñõîäíûõ äàííûõ íåâîçìîæíî «èñïå÷ü» õîðîøèé ìåòà-àíàëèç, âåäü îí íå ãåíåðèðóåò íîâûå äàííûå, à òîëüêî ðåäóöèðóåò óæå èìåþùèåñÿ. Ïîýòîìó âîïðîñ êà÷åñòâà ìåòà-àíàëèçà óïèðàåòñÿ â àíàëèç êà÷åñòâà ïåðâè÷íûõ èññëåäîâàíèé è îòáîð è èñêëþ÷åíèå íåêà÷åñòâåííûõ.  äàííîì ñëó÷àå àâòîðû ÷åñòíî ïèøóò, ÷òî àíàëèç êà÷åñòâà íå ïðîâîäèëñÿ è âêëþ÷àëîñü âñå ïîäðÿä, à áîëåå êà÷åñòâåííûå äàííûå ÐÊÈ ðåäóöèðîâàëèñü äî óðîâíÿ íàáëþäåíèé ñåðèé ñëó÷àåâ. Îïèñàíèå ñåðèé ñëó÷àåâ èìåþò öåëûé âîðîõ «âñòðîåííûõ» íåäîñòàòêîâ, êîòîðûå õîðîøî èçâåñòíû – ýòî ñèñòåìàòè÷åñêèå îøèáêè îòáîðà, àíàëèçà è èíòåðïðåòàöèè äàííûõ ïðèâîäÿùèå ê çíà÷èòåëüíîìó ïðåóâåëè÷åíèþ ýôôåêòèâíîñòè. Íî åùå åñòü è ñìåøèâàíèå ýôôåêòîâ, êîãäà íà ðåàëüíûå èñõîäû îêàçûâàþò âëèÿíèå íåó÷òåííûå (èëè ïîòåíöèàëüíî íåó÷òåííûå) ôàêòîðû. Âîçâðàùàÿñü ê äàííîìó àíàëèçó, íàïðèìåð, âîçìîæåí òîò ôàêò, ÷òî ëå÷åíèå ýíäîâàñêóëÿðíûì ëàçåðîì âûïîëíÿëîñü â ñïåöèàëèçèðîâàííûõ âûñîêîòåõíîëîãè÷åñêèõ öåíòðàõ, à õèðóðãè÷åñêîå ëå÷åíèå – â àíàëîãàõ íàøèõ ÖÐÁ, ãäå óðîâåíü óõîäà ïîñëå âìåøàòåëüñòâà îêàçûâàåò áîëüøå âëèÿíèÿ, ÷åì ñàìî âìåøàòåëüñòâî (ýòî òîëüêî ïîòåíöèàëüíûé ïðèìåð, à íå óòâåðæäåíèå).

Ïîýòîìó îñíîâíîé öåëüþ ñèñòåìàòè÷åñêèõ îáçîðîâ îáñåðâàöèîííûõ èññëåäîâàíèé ÿâëÿåòñÿ íå ãåíåðàöèÿ ÷èñëîâîãî ïîêàçàòåëÿ ýôôåêòèâíîñòè, à àíàëèç ðàçëè÷èé â íàáëþäàåìûõ ýôôåêòàõ (ãåòåðîãåííîñòè) è ãåíåðàöèÿ ãèïîòåç îá ýôôåêòèâíîñòè, íóæäàþùèõñÿ â ýêñïåðèìåíòàëüíîé ïðîâåðêå.
 ìåòà-àíàëèçàõ ÐÊÈ îäíèì èç ïîëåçíûõ ìåòîäîâ ïðîâåðêè ãåòåðîãåííîñòè ðåçóëüòàòîâ ïåðâè÷íûõ ÐÊÈ ÿâëÿåòñÿ ïîñòðîåíèå «âîðîíêîîáðàçíîãî ãðàôèêà», êîòîðûé äîëæåí ïðîäåìîíñòðèðîâàòü áîëåå-ìåíåå ðàâíîìåðíîå ðàñïðåäåëåíèå âåëè÷èíû ýôôåêòà èíäèâèäóàëüíûõ èññëåäîâàíèé â âèäå ïåðåâåðíóòîé âîðîíêè, íà âåðøèíå êîòîðîé íàõîäÿòñÿ ðåçóëüòàòû íàèáîëåå êðóïíûõ ÐÊÈ, à ðåçóëüòàòû áîëåå ìàëî÷èñëåííûõ ìîãóò, è äîëæíû, îòêëîíÿòüñÿ êàê â òó, òàê è â äðóãóþ ñòîðîíó. Íî ïðè àíàëèçå íàáëþäåíèé òàêîé ãðàôèê ïîìîãàåò ìàëî, òàê êàê èìååòñÿ ìàññà ïðè÷èí äëÿ îòêëîíåíèé. Íàïðèìåð, ñèñòåìàòè÷åñêàÿ îøèáêà ïóáëèêàöèè òîëüêî ïîëîæèòåëüíûõ ðåçóëüòàòîâ. Êàæäûé àâòîð è êàæäûé ðåäàêòîð ñòðåìèòñÿ îïóáëèêîâàòü êàêîå-òî äîñòèæåíèå, à îòðèöàòåëüíûå ðåçóëüòàòû âñåãäà ïóáëèêóþòñÿ (åñëè ïóáëèêóþòñÿ) ïîçæå ïîëîæèòåëüíûõ. Íàãëÿäíî âèäíî èç ðèñóíêà 2, ÷òî äëÿ ïðîöåäóðû EVLA âîîáùå íåò îòðèöàòåëüíûõ ðåçóëüòàòîâ, à åñëè ïîïûòàòüñÿ ïîñòðîèòü «âîðîíêîîáðàçíûé ãðàôèê» äëÿ EVLA, òî îêàæåòñÿ, ÷òî îí áóäåò âûðàæåíî àññèìåòðè÷íûé, ïðè÷åì íàèáîëüøàÿ ýôôåêòèâíîñòü îêàæåòñÿ ó íàèáîëåå êðóïíûõ íàáëþäåíèé – ÷òî ãîâîðèò î âûðàæåííîì ïðåóâåëè÷åíèè ýôôåêòèâíîñòè ýòîãî âìåøàòåëüñòâà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 11.11.2009, 15:23
LupusDoc LupusDoc âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 04.08.2007
Ãîðîä: RUSSIA
Ñîîáùåíèé: 4,176
Ïîáëàãîäàðèëè 1,091 ðàç(à) çà 998 ñîîáùåíèé
LupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ïðîäîëæåíèå

Îòäåëüíî ñëåäóåò ðàçîáðàòü âîïðîñ î ìåòà-ðåãðåññèîííîì àíàëèçå çàâèñèìîñòè ýôôåêòà ïðîöåäóð îò âðåìåíè (ðèñóíîê 3). ß íå ÿâëÿþñü ñïåöèàëèñòîì â îáëàñòè ëå÷åíèÿ âàðèêîçíûõ âåí, îäíàêî äàííûå ãðàôèêè ãîâîðÿò î òîì, ÷òî äëÿ õèðóðãèè, ñêëåðîòåðàïèè, RFA íàáëþäàåòñÿ îäèíàêîâàÿ òåíäåíöèÿ – ïàäåíèå ýôôåêòèâíîñòè ñ òå÷åíèåì âðåìåíè ïîñëå ïðîöåäóðû, ÷òî âïîëíå ëîãè÷íî ñ òî÷êè çðåíèÿ êëèíèöèñòà – âîçìîæíà ðåêàíàëèçàöèÿ ñêëåðîçèðîâàííûõ âåí, íåïîëíîå óäàëåíèå âåòâåé ïðè õèðóðãè÷åñêîì âìåøàòåëüñòâå, è ðàíåå íîðìàëüíûå âåíû ñòàíîâÿòñÿ âàðèêîçíûìè – è äð. âåðîÿòíûå îáúÿñíåíèÿ. Íî äëÿ EVLA òåíäåíöèÿ îáðàòíàÿ – ÷åì áîëüøå âðåìåíè ïîñëå âìåøàòåëüñòâà – òåì ëó÷øå ýôôåêò – êàêîå ýòîìó ìîæåò áûòü êëèíè÷åñêîå îáúÿñíåíèå? Ðàçâå ÷òî ëàçåð çàñåëÿåò âåíû «àíãåëàìè», êîòîðûå â òå÷åíèå 3 ëåò äîáðîñîâåñòíî è òùàòåëüíî «ïîä÷èùàþò» âñå âàðèêîçíûå âåíû… Íî ìîæåò ÿ íàñòîëüêî äàëåê îò ýòèõ ìåòîäèê, ÷òî íå çíàþ ðåàëüíîãî êëèíè÷åñêîãî îáúÿñíåíèÿ ýòîìó ôåíîìåíó. Ñ òî÷êè æå çðåíèÿ ñòàòèñòèêà îáúÿñíåíèå î÷åíü òðèâèàëüíîå – áîëüøèíñòâî èññëåäîâàíèé EVLA êðàòêîñðî÷íûå è òîëüêî îäíî èìåëî ïðîäîëæèòåëüíîñòü íàáëþäåíèÿ 36 ìåñÿöåâ, äâà – 24 ìåñÿöà è 7 – 12 ìåñÿöåâ. Òî åñòü òàêîé òðåíä – ïðîñòî ñòàòèñòè÷åñêàÿ ôëóêòóàöèÿ, ñâÿçàííàÿ ñ ïðåóâåëè÷åíèåì ýôôåêòèâíîñòè â íåêîíòðîëèðóåìûõ èññëåäîâàíèÿõ.
Íî îñîáåííî îãîð÷àåò òî, ÷òî àâòîðû ðåøèëè ýêñòðàïîëèðîâàòü òðåíä è ïðèâîäÿò â òàáëèöå 2 ñâåäåíèÿ î 5-òè ëåòíåé ýôôåêòèâíîñòè EVLA, êîòîðàÿ ïî èõ ìíåíèþ îêàçàëàñü âûøå äðóãèõ ìåòîäèê… Ïðàâäà íåò îáúÿñíåíèé òîìó, ÷òî ïðè ðàçíîíàïðàâëåííûõ òðåíäàõ çíà÷èìî áîëåå ýôôåêòèâíîå ïî ìíåíèþ àâòîðîâ ÷åðåç 3 ìåñÿöà è ÷åðåç 1 ãîä âìåøàòåëüñòâî EVLA òåðÿåò çíà÷èìî áîëüøóþ ýôôåêòèâíîñòü ÷åðåç 3 è 5 ëåò… Íî äàæå ýòî íå îñòàíàâëèâàåò ñìåëûõ èññëåäîâàòåëåé è îíè óòâåðæäàþò â òàáëèöå 3, ÷òî äàæå ïðè êîððåêòèðîâêå ïî âðåìåíè íàáëþäåíèÿ EVLA çíà÷èìî ýôôåêòèâíåå äðóãèõ ìåòîäîâ. È ýòî íåñìîòðÿ íà òî, ÷òî 4 èç 13 (30%) èññëåäîâàíèé õèðóðãè÷åñêîãî âìåøàòåëüñòâà ïðåâûøàëè ìàêñèìàëüíûé ñðîê íàáëþäåíèÿ â 30 èññëåäîâàíèÿõ EVLA.

Îñòîðîæíîå çàêëþ÷åíèå àâòîðîâ ïîíÿòíî – áåç òàêîâîãî ðåäàêòîð íå ïðîïóñòèë áû ñòàòüþ ê ïóáëèêàöèè. Íî äàæå è òàêîå çàêëþ÷åíèå èçëèøíå îïòèìèñòè÷íî. Ìîæíî ñîãëàñèòüñÿ ëèøü ñ òåì, ÷òî òðåáóåòñÿ ïðîâåäåíèå êðóïíûõ ÐÊÈ ïî èçó÷åíèþ ýôôåêòèâíîñòè ýíäîâàñêóëÿðíûõ âìåøàòåëüñòâ, íî ñâåäåíèÿ î áîëåå âûñîêîé ýôôåêòèâíîñòè EVLA î÷åâèäíî ïðåóâåëè÷åíû – íè îäíîãî ÐÊÈ íå áûëî (!!!), â ëó÷øåì ñëó÷àå ìîæíî ãîâîðèòü î ñîïîñòàâèìîé ñ äðóãèìè ìåòîäàìè ýôôåêòèâíîñòè.

 öåëîì, ðàáîòà âûçûâàåò ãðóñòíûå ÷óâñòâà – îíà èìååò àäåêâàòíóþ öåëü è î÷åâèäíóþ àêòóàëüíîñòü, íî àâòîðû íå ñìîãëè èçáåæàòü ñîáëàçíà – äàëåêî íå âñåãäà òðåáóåòñÿ ïðîâåäåíèå êîëè÷åñòâåííîãî ìåòà-àíàëèçà ïðè âûïîëíåíèè ñèñòåìàòè÷åñêîãî îáçîðà îáñåðâàöèîííûõ èññëåäîâàíèé, íî æåëàíèå ïîëó÷èòü êîëè÷åñòâåííóþ îöåíêó â äàííîì ñëó÷àå ïåðåâåñèëî. Âàëèäíîñòü òàêîé êîëè÷åñòâåííîé îöåíêè íè÷òîæíà ïî ñëåäóþùèì ïðè÷èíàì:
- ñåðèè ñëó÷àåâ îáëàäàþò ìíîæåñòâîì ñèñòåìàòè÷åñêèõ îøèáîê, ïðèâîäÿùèõ ê ïðåóâåëè÷åíèþ ýôôåêòèâíîñòè è åñòü ìàññà ïðèìåðîâ, â êîòîðûõ ýôôåêòèâíûå â ñåðèÿõ ñëó÷àåâ âìåøàòåëüñòâà îêàçûâàëèñü íåýôôåêòèâíûìè â ÐÊÈ;
- èìååòñÿ î÷åâèäíàÿ ñèñòåìàòè÷åñêàÿ îøèáêà ïóáëèêàöèè ïîëîæèòåëüíûõ äàííûõ, ïî êðàéíåé ìåðå â îòíîøåíèè EVLA;
- â àíàëèç áûëè âêëþ÷åíû èññëåäîâàíèÿ ñ ðàçíûì äèçàéíîì, ÷òî ñîâåðøåííî íåäîïóñòèìî. Ìàíèïóëÿöèÿ ñ ïåðåâîäîì äàííûõ ÐÊÈ â ôîðìàò ñåðèé ñëó÷àåâ ëèøü äîïîëíèòåëüíî ïîäðûâàåò âàëèäíîñòü ìåòà-àíàëèçà;
- ïðèìåíåíèå ìåòà-ðåãðåññèè â êà÷åñòâå îñíîâíîãî ìåòîäà îöåíêè ýôôåêòèâíîñòè âìåøàòåëüñòâ ñ÷èòàåòñÿ íåäîïóñòèìîé;
- èìåþòñÿ ïðîáëåìû ñ îòáîðîì èññëåäîâàíèé äëÿ âêëþ÷åíèÿ â ìåòà-àíàëèç, ñîìíèòåëüíàÿ âàëèäíîñòü âûáðàííîé àâòîðàìè ïðîèçâîëüíîé êîíå÷íîé òî÷êè, êîòîðàÿ ñàìà ïî ñåáå ÿâëÿåòñÿ âòîðè÷íîé (ò.ê. àâòîðû îáçîðà îïðåäåëÿëè «óñïåøíîñòü» è «íåóñïåøíîñòü» ïðîöåäóðû);
- ñóùåñòâåííûå ïðîáëåìû ñ ðàçíûìè ïåðèîäàìè íàáëþäåíèÿ, êîòîðûå ïðèâåëè ê ýêñòðàïîëÿöèè, à íå àíàëèçó äàííûõ.

Êîììåíòàðèè ê ñîîáùåíèþ:
aberzoy îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 11.11.2009, 15:26
LupusDoc LupusDoc âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 04.08.2007
Ãîðîä: RUSSIA
Ñîîáùåíèé: 4,176
Ïîáëàãîäàðèëè 1,091 ðàç(à) çà 998 ñîîáùåíèé
LupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåLupusDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Îêîí÷àíèå

Ñëîæèëîñü âïå÷àòëåíèå, ÷òî ïî áîëüøåé ÷àñòè ðàáîòà ïðåäñòàâëÿåò ñîáîé ñòàòèñòè÷åñêèé ýêçåðöèñ, îòîðâàííûé îò êëèíè÷åñêèõ ðåàëèé – à ìû âîò ÷òî ìîæåì íààíàëèçèðîâàòü! Àâòîðû îñîçíàþò îãðàíè÷åíèÿ èõ ìåòà-àíàëèçà, î ÷åì ñîîáùàþò â ðàçäåëå îáñóæäåíèå: “This rather unusual but methodologically and clinically sound approach was chosen because of the lack of comparative RCTs in phlebology, as was illustrated by the systematic review.” È åñëè ñ ïåðâîé ÷àñòüþ óòâåðæäåíèÿ íåëüçÿ íå ñîãëàñèòüñÿ – ÷òî âûáðàí î÷åíü íåîáû÷íûé ïîäõîä, òî âòîðàÿ ÷àñòü – î ìåòîäîëîãè÷åñêîé è êëèíè÷åñêîé îáîñíîâàííîñòè âûçûâàåò áîëüøèå ñîìíåíèÿ.
Àâòîðû óêàçûâàþò, ÷òî îíè âûïîëíèëè íåñêîëüêî àíàëèçîâ ÷óâñòâèòåëüíîñòè, êîòîðûå ïîäòâåðäèëè îñíîâíîå çàêëþ÷åíèå, íî íå ïðèâîäÿò ðåçóëüòàòû ýòèõ àíàëèçîâ.

È ýòà ðàáîòà äåéñòâèòåëüíî ñîîòâåòñòâóåò ñâîåìó íàçâàíèþ – èçîùðåííûé è âðÿä ëè âàëèäíûé ìåòà-àíàëèç íàñòîëüêî ïðåâàëèðóåò íàä ñèñòåìàòè÷åñêèì îáçîðîì, ÷òî íå îñòàâëÿåò âîçìîæíîñòè ïîäóìàòü î ðåàëüíûõ ïðåèìóùåñòâàõ âûïîëíåíèÿ òàêîãî ñèñòåìàòè÷åñêîãî îáçîðà. Èìåííî èç-çà òàêèõ àíàëèçîâ åñòü ìíåíèå, ÷òî ìåòà-àíàëèçû îáñåðâàöèîííûõ èññëåäîâàíèé áåñïîëåçíû [Shapiro S. Meta-analysis/Shmeta-analysis. Am J Epidemiol 1994;140:771-8]. Íî âåäü àâòîðû ìîãëè îòâåòèòü íà âîïðîñû, êîòîðûå òðóäíî èññëåäîâàòü â ÐÊÈ – â ïåðâóþ î÷åðåäü, î áåçîïàñíîñòè ýíäîâàñêóëÿðíûõ ìåòîäèê â ñðàâíåíèè ñ õèðóðãèåé, ÷åãî, óâû, ñäåëàíî íå áûëî.

Íåêîòîðûå òåõíè÷åñêèå ìîìåíòû ïóáëèêàöèè íàñòîðàæèâàþò (õîòÿ ýòî ìîæåò áûòü è èçëèøíèì ïðåäóáåæäåíèåì):
- îòñóòñòâóþò ññûëêè íà ïåðâè÷íûå èññëåäîâàíèÿ, ÷òî äåëàåò íåâîçìîæíûì ñàìîñòîÿòåëüíóþ ïåðåïðîâåðêó ïåðâè÷íûõ äàííûõ. Ýòî ìîæíî îáúÿñíèòü îãðàíè÷åíèÿìè ïå÷àòíîé âåðñèè, íî â òàêîì ñëó÷àå ïðèíÿòî âûíîñèòü ñïèñîê èññëåäîâàíèé â ýëåêòðîííîå ïðèëîæåíèå, î ÷åì äåëàåòñÿ ñíîñêà â òåêñòå ïóáëèêàöèè.
- â îáñóæäåíèè óïîìèíàåòñÿ ÐÊÈ, êîòîðîå íàïðÿìóþ ñðàâíèâàëî EVLA è õèðóðãè÷åñêîå âìåøàòåëüñòâî [24], íî â ìåòà-àíàëèç îíî íå âîøëî, ïî êàêèì ïðè÷èíàì – íåèçâåñòíî… Íî ýòî ÐÊÈ íå ïðîäåìîíñòðèðîâàëî ïðåâîñõîäñòâà EVLA íàä õèðóðãèåé, îáíàðóæåííîå àâòîðàìè.
- íà forrest plots íå âåçäå åñòü ïîäïèñè ê äàííûì (âåðîÿòíî – ýòî òåõíè÷åñêàÿ îøèáêà, íî, ÈÌÕÎ, ðåäàêòîð è àâòîðû íå äîëæíû áûëè ïðîïóñòèòü ýòî ê ïóáëèêàöèè ïðè proofreading)
- áîëåå 20% íåóñïåõà õèðóðãè÷åñêîãî âìåøàòåëüñòâà â òå÷åíèå 1 ãîäà íàáëþäåíèÿ çàñòàâëÿþò ìåíÿ ñîìíåâàòüñÿ â êà÷åñòâå îïåðàòèâíîãî ëå÷åíèÿ – íî ÿ íå ñïåöèàëèñò è ìîãó íåâåðíî ïîíèìàòü êðèòåðèè ýôôåêòèâíîñòè. Íî ñ òî÷êè çðåíèÿ ïàöèåíòà, åñëè ïåðåä îïåðàöèåé ñêàæóò – «ó Âàñ øàíñ îäèí ê ïÿòè, ÷òî îïåðàöèÿ áóäåò íåóñïåøíîé» ÿ áû ñèëüíî çàäóìàëñÿ, ñîãëàøàòüñÿ ëè íà òàêîå âìåøàòåëüñòâî…
- â òàáëèöå 2 åñòü ðàñ÷åòû ïðîïîðöèè ïàöèåíòîâ, ó êîòîðûõ EVLA ýôôåêòèâíà â ïåðèîäå íàáëþäåíèÿ 5 ëåò, íî èç òàáëèöû 1 ñëåäóåò, ÷òî ìàêñèìàëüíûé ñðîê íàáëþäåíèÿ â ýòîé ïîäãðóïïå ñîñòàâèë âñåãî 3 ãîäà.

Òàêèì îáðàçîì, íåñìîòðÿ íà íåñîìíåííóþ öåííîñòü ñèñòåìàòè÷åñêîãî îáçîðà, âûïîëíåíèå ìåòà-àíàëèçà áûëî íå îïðàâäàííûì è â òîì âèäå, êàê åñòü, îí íå ìîæåò ñ÷èòàòüñÿ âàëèäíûì. Ê çàêëþ÷åíèÿì àâòîðîâ î áîëåå âûñîêîé ýôôåêòèâíîñòè EVLA ñëåäóåò îòíåñòèñü êàê ê íåäîñòàòî÷íî îáîñíîâàííûì.

Íåêîòîðûå ññûëêè î ìåòà-àíàëèçàõ âîîáùå è ìåòà-àíàëèçàõ îáñåðâàöèîííûõ èññëåäîâàíèé â ÷àñòíîñòè:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
  1. Egger M, Davey Smith G. Meta-analysis: potentials and promise. BMJ 1997;315:1371-4.
  2. Egger M, Davey Smith G, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-7.
  3. Davey Smith G, Egger M, Phillips AN. Meta-analysis: beyond the grand mean? BMJ 1997;315:1610-4.
  4. Egger M, Davey Smith G. Meta-analysis: bias in location and selection of studies. BMJ 1997;315:61-66.
  5. Egger M, Davey Smith G, Schneider M, Minder CE. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
  6. Ioannidis, J. P A, Patsopoulos, N. A, Rothstein, H. R. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008; 336: 1413-1415
  7. Elm, E. v., Altman, D. G, Egger, M., Pocock, S. J, Gotzsche, P. C, Vandenbroucke, J. P, STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-808
  8. Hartling, L., McAlister, F. A., Rowe, B. H., Ezekowitz, J., Friesen, C., Klassen, T. P. Challenges in Systematic Reviews of Therapeutic Devices and Procedures. Ann Intern Med 2005; 142: 1100-1111

Êîììåíòàðèè ê ñîîáùåíèþ:
dav1972 îäîáðèë(à): Âàõ!!! Ñïàñèáî!
Vlad34 îäîáðèë(à): â ìåìîðèç.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 11.11.2009, 23:37
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,879
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé LupusDoc! ß íå íàäåÿëñÿ íà ñòîëü ïîäðîáíûé àíàëèç. Î÷åíü ïðèçíàòåëåí. ×èòàë íå òîëüêî ñ èíòåðåñîì, íî è ñ áîëüøèì óäîâîëüñòâèåì. Ïîæàëóé, òåïåðü ìíå íàäî âñå ýòî ïåðåâàðèòü è ïàðó ðàç ïðîéòèñü ïî òåêñòó ñ ó÷åòîì êîììåíòàðèåâ. Åñëè â äåòàëÿõ êîå-÷òî íåïîíÿòíî, òî ñóòü ðàññóæäåíèé è êðèòèêè, êàæåòñÿ, ñîâåðøåííî ÿñíû.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 15:48.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.